Tempus, a leader in artificial intelligence and precision medicine, announced the integration of its signature Tempus One technology into its Lens data analytics platform. AI-enabled Tempus One technology leverages advances in generative AI to seamlessly analyze Tempus’ anonymized multimodal data library to glean insights, build patient cohorts, and explore patient populations. We provide researchers with the tools they need to
“Incorporating our generative AI capabilities into Lens will improve the platform’s capabilities for users and make it easier to leverage our data and insights.”
Tempus One was widely released to physicians at the 2023 ASCO® Annual Meeting. Designed as an AI-enabled clinical assistant, it enables quick and easy queries by voice or typing, leverages access to a patient’s complete clinical and molecular profile, and combines all relevant information. Masu. Guidelines for insights into the latest standards of care. This generative AI technology is now being deployed to his Tempus research collaborators within the Tempus Lens platform to more seamlessly identify and analyze cohorts of interest, answer questions faster, and generate deeper insights. You can get it.
Recommended AI news: Public availability of Liminal safely unlocks generated AI for regulated industries
Tempus One’s integration into Lens begins by incorporating user Q&A via an in-app chat assistant that leverages the large-scale language model (LLM) across the Lens platform. This makes it easier for researchers to access vast amounts of data through enhanced functionality. Support function. Users can submit questions directly in the chat, receive real-time answers with quotes and links to additional information, and provide feedback on the quality of chat responses. This integration also includes LLM-facilitated cohort construction technology that allows users to more quickly size and search patient cohorts across 100 clinical and molecular attributes in Tempus’ datasets. Become.
“We look forward to expanding our Tempus One technology to our life sciences collaborators,” said Ryan Fukushima, Chief Operating Officer of Tempus. “Incorporating our generative AI capabilities into Lens will improve the platform’s capabilities for users and make it easier to leverage our data and insights.”
Recommended AI news: Vade powers spear-phishing detection with generative AI for next-generation threats
[To share your insights with us as part of editorial or sponsored content, please write to sghosh@martechseries.com]
